Abstract
Introduction
At present, obesity is a worldwide health problem and continues to increase due to changes in dietary habits and sedentary lifestyles [1] . Moreover, obesity is a common risk factor for non-alcoholic fatty liver disease (NAFLD), which causes a chronic hepatic pathology and affects numerous people around the world [1] [2] [3] . Thus, it is important to develop effective biomarkers for screening the populations at risk.
The liver is an important organ that regulates glycogen deposition, lipogenesis, fatty acid oxidation and cholesterol transport [4] . Liver X receptor (LXR) belongs to the nuclear receptor superfamily of ligand-activated transcription factors [4, 5] . Two major isoforms have been identified for LXR, including LXRα and LXRβ [4, 6] . Through interaction with the endogenous or synthetic ligands, LXRα plays a key role in the liver. LXRα can bind the retinoid X receptor (RXR), thereby activating the transcription of downstream genes [7] . In the liver, LXRα is found to activate SREBP-1 gene transcription, which then enhances the subsequent activation of lipogenic genes, including fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC1), and stearoyl-coenzyme A desaturase (SCD-1) [8] .
MicroRNAs (miRNAs) are a class of short, noncoding RNAs that widely modulate gene expression [9, 10] . Initially, microRNAs are transcribed as long primary transcripts and then processed by the ribonuclease III endonucleases Drosha and Dicer to form mature 22-nucleotide non-coding small RNAs. Through a base-pairing mechanism, the mature miRNAs can bind to the 3′-untranslated region (UTR) of their target mRNAs, resulting in mRNA degradation [11] . Abnormal expression of miRNAs has been widely identified in different physiological and pathological circumstances [12] [13] [14] . For instance, miR-291b-3p was recently found to prompt hepatic lipogenesis mainly by targeting AMPKα1, and miR-125b enhances lipogenesis through binding the 3'UTR of SCD-1 [12, 13] . In the current study, we mainly focus on miR-155, which has been widely explored in tumors [15, 16] . For instance, ESAT-6 secreted by Mycobacterium Tuberculosis was reported to enhance the apoptosis of macrophages via disturbing the microRNA155-SOCS1 interaction [17] . However, its specific role in NAFLD has never been explored. Here, we first demonstrated that the level of miR-155 was significantly decreased in the livers and peripheral blood of NAFLD patients. Further study revealed that reduction of miR-155 enhanced hepatic lipogenesis mainly by binding the 3'UTR of LXRα.
Materials and Methods
Human liver specimens All peripheral whole blood samples of NAFLD patients (n=50) and healthy individuals (n=50) were obtained from the Second Medical School of Nanjing University of Chinese Medicine between May 2015 and January 2016. The human liver biopsies and clinical procedures were performed with patient consent within the diagnostic workup of NAFLD.
For liver biopsies, a total of 11 patients diagnosed with NAFLD and 11 healthy control subjects were included in the study. Physical examinations, biochemical measurements, and body mass index (BMI) calculations were performed on all of the study participants.
The application for patient-derived materials was approved by the Research Ethics Committee of Second Medical School of Nanjing University of Chinese Medicine, and written consent was obtained from all of the patients.
Animal treatment
Four-week-old wild-type (WT) C57BL/6J mice were purchased from the Peking University Health Science Center. C57BL/6J mice were fed a standard chow diet or a high fat diet (HFD) for 10 weeks in a temperature-(20-24°C) and humidity-controlled (45-55%) environment. A 12 h/12 h light/dark cycle was maintained for the animal housing rooms. HFD-fed mice were injected intravenously through the tail vein with an adenovirus expressing miR-155 inhibitor (Ad-155i) or a negative control (Ad-Con) adenoviral vector for 1 week. On day 7 after adenovirus injection, the mice were anesthetized, and blood was collected via cardiac
RNA isolation and real-time PCR
The total RNA from the whole blood samples (5 ml) collected in tubes containing EDTA was rigorously extracted with RNAVzol LS (Vigorous Biotechnology, Beijing) according to the manufacturer's instructions. Stem-loop reverse transcription-polymerase chain reaction (RT-PCR) was conducted with the samples to detect and quantify mature miRNAs by using stem-loop antisense primer mix and M-MuLV transcriptase (NEB).
The SYBR Green I method was used for real-time PCR with the Bio-Rad iQ5 system (Bio-Rad) according to the manufacturer's instructions (TaKaRa) The relative expression level of a miRNA was normalized to an internal invariant control, U6 small nucleolar RNA. Each reaction was performed in triplicate, and analysis was performed using the 2 -△△CT method.
Western blot analysis
A total of 15 µg protein was separated by 10% SDS-PAGE and then transferred to PVDF membrane (Millipore), followed by 8% nonfat dry milk blocking. After washing with PBST three times (5 min/wash), the membranes were incubated with primary antibodies at 4°C overnight. The blot was incubated with HRP-conjugated anti-IgG, followed by detection with ECL (Millipore). Antibodies against LXRα (ab28478) were purchased from Abcam. FAS (#3180) and β-actin (#4970) were obtained from Cell Signaling Technology. An antibody against SREBP1 was purchased from Santa Cruz Biotechnology (sc-366).
Triglyceride measurement
The content of tissue triglycerides was measured as described previously [18, 19, 20 ] using a triglyceride enzymatic assay kit (ShenSuoYouFu Medical Diagnostic Products Co., Ltd., Shanghai, China).
Histological analysis of tissues
Frozen sections of livers were paraformaldehyde-fixed for Oil red O or hematoxylin and eosin (H&E) staining.
Luciferase reporter assay
The 3'UTR sequence of LXRα predicted to interact with miR-155 was cloned from the genomic DNA of the Hep1-6 cell line and inserted into the XbaI and SacI sites of the pmir-GLO control luciferase reporter vector (Promega, Madison, WI). HEK293 cells were co-transfected with internal control vector pmir-GLO (Promega), pmir-GLO-SREBP1 3'UTR and miR-155 mimics (or negative control) using Effectene (Qiagen) for 48 h. Luciferase reporter assays were performed using the Dual-Glo Luciferase assay system according to standard protocols (Promega).
Statistics
The data are represented as means ± standard error of the mean (SEM). Differences were analyzed by Student's t-test with significance set at P<0.05. control subjects using real-time PCR. As shown in Fig. 1C , the expression of miR-155 was significantly suppressed in the peripheral blood of NAFLD patients compared with that of healthy controls (P<0.001). The relative expression of miR-155 was 0.13±0.045 for NAFLD patients and 1±0.35 for healthy controls. Furthermore, we have also tested the expression of LXR-sensitive genes in the livers of NAFLD patients who have a reduced miR-155 level. According to our analysis,
Reduction of miR-155 contributed to abnormal upregulation of lipogenic genes
Next, we explored the role of miR-155 on lipid accumulation in Hep1-6 cells. As shown in Fig. 2A , overexpression of miR-155 markedly suppressed the protein level of SREBP1 and FAS. Meanwhile, the intracellular contents of lipids were also significantly decreased (Fig.  2B) . In contrast, inhibition of miR-155 significantly enhanced the expression of SREBP1 and FAS in Hep1-6 cells transfected with miR-155 inhibitor (Fig. 2C) . More importantly, the intracellular contents of triglyceride were significantly increased when the level of miR-155 was suppressed (Fig. 2D) .
Overexpression of miR-155 could abolish oleic acid/ palmitic acid (O/P)-induced lipid accumulation
To further explore whether upregulation of miR-155 ameliorates lipid accumulation, the Hep1-6 cells were pre-treated with free fatty acid, a mixture of oleic acid/ palmitic acid (O/P) with a final concentration of 300 μM. Large lipid droplets were shown in Hep1-6 cells pre-incubated with O/P (Fig. 3A) . In comparison, overexpression of miR-155 reduced the lipid droplets in Hep1-6 cells in the presence of O/P (Fig. 3A) . Western blot analysis demonstrated that the expression of lipogenic genes, including SREPB1 and FAS, was significantly increased in Hep1-6 cells (Fig. 3B) . In contrast, transfection with miR-155 mimic could partially abolish such effects (Fig. 3B) .
LXRα was the target gene of miR-155
Then, we investigated the possible target gene of miR-155 that is involved in lipogenesis. Interestingly, a conserved binding site for miR-155 on the 3'UTR of LXRα was identified through TargetScan (http://www.targetscan.org/vert_71/) (Fig. 4A) . Then, the 3'UTR of LXRα was cloned into the dual luciferase reporter, pmirGLO. As shown in Figure 4B , overexpression of miR-155 significantly suppressed the relative luciferase activity of pmirG-LO-LXRα-3'UTR compared with the blank vector (Fig. 4B ). Meanwhile, the protein level of LXRα was significantly suppressed in Hep1-6 cells transfected with miR-155 mimic (Fig.  4C) , while the level of LXRα was markedly increased in Hep1-6 cells transfected with miR-155 inhibitor (Fig. 4D) . Immunofluorescence analysis also confirmed that upregulation of miR-155 decreased the fluorescence of LXRα (Fig. 4E) . These data indicated that LXRα was the target gene of miR-155.
Silence of LXRα decreased lipid accumulation in Hep1-6 cells
Furthermore, the expression of LXRα was silenced by two specific siRNAs. As shown in Fig. 5A , knockdown of LXRα significantly inhibited the protein levels of SREBP1 and FAS in Hep1-6 cells. Meanwhile, the lipid droplets were decreased in Hep1-6 cells transfected with siRNAs targeting LXRα (Fig. 5B) . More importantly, we determined that inhibition of miR-155 could partially reverse LXRα inhibition-induced downregulation of SREBP1 and FAS in Hep1-6 cells (Fig. 5C) .
Upregulation of miR-155 decreased lipid accumulation in HFD-fed mice
Based on the in vitro study, we further extended our research into the in vivo setting. Through tail vein injection, the ad-miR-155m or ad-NC was delivered to the livers of HFD fed mice. The livers of HFD-fed mice transfected with ad-miR-155m were significantly reduced compared with those transfected with ad-NC (Fig. 6A) . Oil Red staining and H&E staining showed that the lipid droplets were reduced in the livers of HFD-fed mice transfected with ad-miR-155m compared with ad-NC (Fig. 6B) . Further study showed that upregulation of miR-155 decreased the hepatic triglyceride contents compared with ad-NC (Fig. 6C) . Meanwhile, the protein levels of LXRα, SREBP1 and FAS were significantly reduced in the livers of HFD-fed mice transfected with ad-miR-155m compared with ad-NC (Fig. 6D) .
Discussion
At present, NAFLD is considered to be a common cause of liver damage [19, 20] . It is reported that abnormal fat deposition in the liver may eventually develop into nonalcoholic steatohepatitis (NASH) and eventually fibrosis [21] . In the past years, researchers have been making great efforts to elucidate the pathogenesis of NAFLD. However, little is known about the underlying mechanism of NAFLD. Increasing evidence has demonstrated that miRNAs play key roles in the pathology of NAFLD [14, 22] .
In the current study, we first demonstrated that the level of miR-155 was decreased in the livers and peripheral blood of NAFLD patients compared with those of healthy controls, suggesting that a decreased miR-155 level may be associated with the progression of NAFLD. Further study demonstrated that inhibition of miR-155 resulted in abnormal lipid accumulation in hepatocytes, whereas overexpression of miR-155 improved lipid accumulation and the expression of lipogenic genes, including SREBP1 and FAS. These data demonstrate a possible role of miR-155 as a biomarker for hepatic lipogenesis.
LXRs are nuclear receptors that widely modulate lipid metabolism, such as cholesterol and bile acids [23] . Initially, LXR was identified as a member of the nuclear receptor superfamily, and it could form an active complex with retinoid X receptor α (RXRα) [24, 25] . LXRα was reported to be highly expressed in liver and it is reported that certain oxysterols and intermediates in the cholesterol synthetic pathway can activate the transcription of LXRα [26] . SREBP1 was well known to regulate the expression of lipogenic genes, including FAS, acetyl CoA carboxylase (ACC) and stearoyl CoA desaturase-1 (SCD1) [27] . It is known that LXRα could bind the promoter of SREBP-1c, thereby stimulating lipid synthesis in the liver [28] .
In the current study, we identified that LXRα was a direct target gene of miR-155. Bioinformatics prediction revealed a conserved binding site of miR-155 in the 3'UTR of LXRα. A dual luciferase assay demonstrated that miR-155 could markedly decrease the luciferase reporter activity of pmirGLO-LXRα-3'UTR compared with a blank vector. We showed that knockdown of LXRα through specific siRNAs could significantly inhibit lipid accumulation both in hepatocytes and livers. We then explored the lipid metabolism-related signaling pathway and found that SREBP1 was also suppressed when LXR was silenced. More importantly, inhibition of miR-155 could partially abolish the LXR silence-induced upregulation of lipogenic genes. These data suggested that upregulation of miR-155 improved lipid accumulation mainly by targeting LXRα.
In summary, decreased expression of miR-155 in the peripheral blood may be utilized as a potential novel biomarker for NAFLD screening mainly by targeting LXRα.
